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Abstract
Purpose of review Fever is common within rheumatology but it is often challenging to identify its source. To do so correctly is
paramount in patients with an underlying inflammatory condition receiving immunosuppressive therapy. This review article
looks at the available evidence and merits of both 18F-fluoro-deoxyglucose positron emission tomography/computed tomogra-
phy (18F-FDG PET/CT) scans and new proposed biomarkers in determining the cause of fever within rheumatology.
Recent findings 18F-FDG PET/CT scans are already an established tool in the detection and diagnosis of malignancy and are
emerging for use in fever of unknown origin. More recently, they have been used to identify rheumatological causes of fever such
as large vessel vasculitis and adult-onset Still’s disease. Within these conditions, biomarkers such as procalcitonin and presepsin
may help to differentiate endogenous from exogenous pyrogens.
Summary 18F-FDG PET/CT scanning shows promise in locating the source of pyrogens and may be superior to other conven-
tional forms of imaging. As evidence and test availability increases, its use is likely to become commonplace in the diagnostic
work-up of fever. Once a source is located, selected biomarkers may be used to confirm a cause.
Keywords Fever . FUO . Rheumatology . Diagnostics . Iimaging . Biomarkers
Introduction
Fever is an adaptive response to pyrogens that frequently pre-
sents rheumatologists with a challenge. In particular, the dif-
ficulty lies in determining the originating location of these
pyrogens and whether they are endogenous or exogenous.
The original definition of fever of unknown origin (FUO)
from Petersdorf and Beeson is a febrile illness lasting for more
than 3 weeks’ duration with a body temperature of >38.3°C on
several occasions and no resulting diagnosis despite extensive
investigations with at least 1 week of inpatient investigation
[1]. In 1991, Durack and Street revised these criteria with two
main changes [2]. Firstly, they shortened the duration of in-
vestigation to either 3 outpatient visits or 3 days of inpatient
investigation, reflecting better access to advanced diagnostics
in modern medicine. Secondly, they divided FUO into four
distinct classes. These are classical FUO, neutropaenic FUO,
nosocomial FUO and HIV-associated FUO. It is important to
make the distinction, as the distribution of underlying aetiol-
ogies will vary between the groups, with more infections seen
in the latter three categories compared with classical FUO.
No final diagnosis is reached in 7–53% of FUO patients [3].
Where a diagnosis is reached, the main causes can be divided
into infection, malignancy and non-infectious inflammation. It
is estimated that 20% cases worldwide are caused by a non-
infectious inflammatory disorder, most commonly large vessel
vasculitis and adult-onset Still’s disease (AOSD) [4].
When a febrile patient already has an established underlying
inflammatory condition, identification between infection and
acute flare is paramount to facilitate correct and safe
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management. To administer immunosuppressive treatment mis-
takenly in infection could be catastrophic. This distinction can be
challenging, and has by and large been based upon clinical rea-
soning. However, recent developments in nuclear imaging and
biomarkers may in future aid the clinician in making this distinc-
tion. This article will look at the utility of these developments
within rheumatology, with the focus on the use of 18F-fluoro-
deoxyglucose positron emission tomography/computed tomog-
raphy (18F-FDG PET/CT) scans in identifying a pyrogen loca-
tion and biomarkers such as procalcitonin for distinguishing the
endogenous from the exogenous.
18F-FDG PET/CT Scanning
18F-FDG PET/CT scans are already an established tool in the
detection and diagnosis of malignancy, and are emerging for
use in fever of unknown origin (FUO) [5]. 18F-fluoro-
deoxyglucose (18F-FDG) is injected into the bloodstream
and enters cells via glucose transporter proteins. Areas of
higher concentration can be visualised using PET/CT imag-
ing. Active transporter proteins take up more 18F-FDG, for
example when there is increased cell metabolism such as in
malignant, infectious and inflammatory processes [6]. Thus, it
differs from traditional CTandMRI scanning in that it looks at
functional rather than anatomical processes. Functional im-
ages allow differentiation between active and residual inflam-
mation with less nephrotoxicity and radiation than a contrast
CT chest, abdomen and pelvis scan [6, 7, 8•].
A fundamental disadvantage of the 18F-FDG PET/CTscan
is that, while often able to locate the source of the pyrogens, it
is unable to distinguish between malignant, infectious or in-
flammatory processes. Instead, it may be used effectively to
guide further investigation [6]. There are issues of cost and
accessibility when compared to CT or MRI scanning, al-
though some of the cost may be negated by reduced hospital
admission length [6, 8•]. A further issue relates to the reliabil-
ity of the results. False positive uptake of 18F-FDG has been
shown to occur in macrophages of atherosclerotic plaques in
the aorta and iliofemoral regions [9•]. Excretion of 18F-FDG
by the kidneys may mask pelvic anomalies, resulting in false
negative results [10]. In addition, 18F-FDG uptake may be
affected by glucocorticoid or other immunosuppressant treat-
ments commonly used within rheumatology [11]. One study
showed glucocorticoid treatment of longer than 10 days dura-
tion to decrease uptake of 18F-FDG [9•].
Evidence for its utility in practice is limited, with no large-
scale studies available. A recent meta-analysis of 18 studies
suggested that 18F-FDG PET/CT scanning provided a 56%
diagnostic contribution in patients with FUO [8•]. Of these
scans, 9% resulted in false positives and 73% patients obtain-
ed a final diagnosis. The authors comment that most of the
studies in the analysis were observational, with no control and
much room for bias. Inevitably, more studies are needed be-
fore definitive answers are provided for its use in FUO.
18F-FDG PET/CT Scanning in Fever of Unknown
Rheumatological Origin
There is a growing body of research focused on the diagnostic
contribution of 18F-FDG PET/CT scanning in specific rheu-
matological conditions. This section looks at the two most
common non-infectious causes of FUO: large vessel vasculitis
and AOSD.
Large Vessel Vasculitis
Large vessel vasculitides such as giant cell arteritis (GCA) and
Takayasu’s arteritis are common inflammatory causes of
FUO. GCA presents with fever in a third of patients and
Takayasu’s arteritis in 20% [12, 13]. 18F-FDG PET/CT scan-
ning has been proposed to be superior to other forms of im-
aging in both forms [14]. This is because, early in the course
of the disease, anatomical changes may be absent and thus
may be missed by conventional imaging, such as CT and
MRI scanning [15]. Furthermore, the gold standard diagnostic
tool for GCA of a superficial temporal biopsy has high false
negative rates of 15–40% due to skip lesions [16]. A system-
atic review showed sensitivities and specificities of 18F-FDG
PET/CTscanning in GCA of 90% and 98% and in Takayasu’s
of 87% and 73%, respectively [17]. Another study looked at
18F-FDG PET/CT scanning in patients with large vessel vas-
culitis compared to those with hyperlipidaemia and vasculitis
mimics, and found that 18F-FDG PET/CT scanning could
differentiate between these with a sensitivity of 85% and spec-
ificity of 83% [18•]. Despite being unable to view the tempo-
ral artery, the characteristic distribution of uptake of 18F-FDG
in the PET/CT scan may be used to distinguish between these
forms of vasculitis. In GCA, 18F-FDG accumulates in the
aorta, subclavian, carotid and iliac arteries, whereas in
Takayasu’s arteritis, it is more centrally located in the aorta
and its main branches in the thoracic region [19].
Adult-Onset Still’s Disease
AOSD has been referred to as the archetypal febrile
autoinflammatory illness [20]. It typically causes a diurnal fever,
highest in the evening accompanied by a salmon pink rash and
arthralgia. Currently, the diagnosis is largely clinical due to low
prevalence, vague symptoms and the absence of any diagnostic
test [21]. Data regarding utility of 18F-FDG PET/CT scanning
are limited, but 18F-FDG has been shown to accumulate in bone
marrow, spleen, lymph nodes and joints in the condition, and
thus may be helpful when combined with clinical features [22].
One limitation is an inability to distinguish AOSD from
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lymphoma. However, it may be used to guide an appropriate site
for biopsy, thus facilitating the correct diagnosis [22].
Use of Biomarkers to Differentiate
Endogenous and Exogenous Pyrogens
While 18F-FDG PET/CT scanning is useful for determining a
location for pyrogens, the differentiation between infection and
acute flare of an autoimmune condition remains a challenge for
the rheumatologist. Standard biomarkers for infection, such as a
white cell count (WCC), erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP), may be elevated in both condi-
tions. An exception to this is in systemic lupus erythematosus
(SLE), where CRP does not typically rise in acute flare but does
in concurrent infections rendering it a useful biomarker for infec-
tion [23]. Microbiological investigations may also have limita-
tions such as temporal delays and low accuracy rates [24].
Procalcitonin
To combat these problems, a hunt for specific biomarkers to aid
differentiation between the two has ensued. One proposed bio-
marker is procalcitonin. This is a precursor of calcitonin which
rises substantially in bacterial infection but not normally in non-
infectious inflammatory diseases [25]. However, a moderate rise
has been seen in active AOSD and vasculitis in the absence of
infection [26]. A meta-analysis of suspected septic arthritis and
osteomyelitis revealed that procalcitonin had a sensitivity of 67%
and specificity of 90%, but, at lower serum concentrations of
procalcitonin, the sensitivity rose to 87% [27]. It has been shown
to differentiate bacterial infection from acute flare in rheumatoid
arthritis, with superiority over conventional biomarkers such as
CRP, ESR andWCC [28]. Conversely, as illustrated earlier, CRP
is a sensitive marker for bacterial infection in SLE and has been
shown to be superior to procalcitonin as a biomarker for this
condition [29]. Concomitant glucocorticoid use does not seem
to affect procalcitonin levels, but evidence for other immunosup-
pressive therapies is lacking [30].
Presepsin
A second proposed biomarker is presepsin. This is a soluble
CD14 subtype which is thought to be released following cellular
phagocytosis in bacterial infections, and has been shown to be
useful in management of sepsis [31, 32]. Evidence for its use in
rheumatology is limited, but one study shows promise and supe-
riority of presepsin over procalcitonin in rheumatoid arthritis pa-
tients with low-grade bacterial infections with a sensitivity and
specificity of 92.3% and 77.8%, respectively [33•]. Another study
suggests that baseline presepsin levels in rheumatoid arthritis pa-
tients without infection is higher than in healthy controls [34].
However, careful use of cut-off values helped to distinguish
between these rheumatoid arthritis patients with and without in-
fection. In addition, their proposed cut-off levels were unaffected
by the use of glucocorticosteroids and methotrexate therapy.
Combined Biomarkers
Finally, a number of studies have considered the utility of com-
bined biomarkers, such as CRP with interleukin-6 (Il-6) in
periprosthetic joint pathology showing superiority over other
biomarkers (including procalcitonin) when distinguishing be-
tween aseptic joint loosening and infection [35•, 36]. Studies
have not yet compared CRP and Il-6 levels in inflammatory
and infectious processes within rheumatological conditions.
Moreover, CRP and Il-6 may both be raised in an acute flare of
such conditions. However, as with presepsin, further research
may reveal a useful cut-off value to help differentiate the two.
In summary, these novel biomarkers show promise in the
differentiation between endogenous and exogenous pyrogens,
but are not yet in routine clinical practice. With further re-
search, they may aid diagnosis in certain patient groups.
Conclusion
Fever can be a very challenging presentation due to its variety
of different aetiologies. Correct and rapid identification is im-
portant and especially so in rheumatology where patients may
be on immunosuppressant therapy. Recent developments have
meant that we may be closer to pinpointing a source of pyro-
gens. 18F-FDG PET/CT scanning can help to locate the pyro-
gens and, with further research, its use may become more
routine in the diagnostic work-up of fever. Consequently, it
may help to diagnose common causes of fever often missed,
such as large vessel vasculitides and AOSD. Concurrent use
of biomarkers may further facilitate diagnosis in the differen-
tiation between endogenous and exogenous pyrogens. In fu-
ture, it may be used by rheumatologists for patients with un-
derlying inflammatory pathology to aid differentiation be-
tween infectious and acute inflammatory flares.
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